Compugen Ltd Revenue Growth Rates (CGEN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Compugen Ltd  (NASDAQ: CGEN)
 

CGEN's Revenue Growth by Quarter and Year

Compugen Ltd's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CGEN Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 72.76
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 72.76

CGENs Annual Revenue
Compugen Ltd's Revenue in the fiscal year 2025 $ 72.76 millions
Compugen Ltd's Revenue in the fiscal year 2024 $ 27.86 millions
Compugen Ltd's Revenue in the fiscal year 2023 $ 33.46 millions
Compugen Ltd's Revenue in the fiscal year 2022 $ 7.50 millions
Compugen Ltd's Revenue in the fiscal year 2021 $ 6.00 millions




CGEN Revenue fourth quarter 2025 Y/Y Growth Comment
Compugen Ltd achieved in the fourth quarter 2025, above Company average Revenue surge of 161.18% year on year, to $ 72.76 millions.

Looking into fourth quarter 2025 results within Biotechnology & Pharmaceuticals industry 15 other companies have achieved higher Revenue growth. While Compugen Ltd' s Revenue doubling of 161.18% ranks overall at the positon no. 230 in the fourth quarter 2025.


CGEN Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 161.18 % 271.47 % 25 % 200 %
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   161.18 % 271.47 % 25 % -

Financial Statements
Compugen Ltd's fourth quarter 2025 Revenue $ 72.76 millions CGEN's Income Statement
Compugen Ltd's fourth quarter 2024 Revenue $ 27.86 millions Quarterly CGEN's Income Statement


CGEN Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   161.18 % 271.47 % 25 % -


Back to CGEN Growth rate Comparisons >> Back to CGEN Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #16
Healthcare Sector #69
Overall #230

Revenue Y/Y Growth Statistics
High Average Low
1366.53 % 143.1 % -100 %
(Dec 31 2013)   (Dec 31 2022)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #16
Healthcare Sector #69
Overall #230
Revenue Y/Y Growth Statistics
High Average Low
1366.53 % 143.1 % -100 %
(Dec 31 2013)   (Dec 31 2022)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Compugen Ltd's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CGEN's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CGEN's IV. Quarter Q/Q Revenue Comment


Compugen Ltd's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 72.76 $ 27.86 $ 33.46 $ 7.50 $ 6.00
Y / Y Revenue Growth (TTM) 161.14 % -16.72 % 346.12 % 25 % 200 %
Year on Year Revenue Growth Overall Ranking # 28 # 22 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 161.14 % -16.72 % 346.12 % 25 % 200 %
Seq. Revenue Growth (TTM) Overall Ranking # 55 # 57 # 0 # 0 # 0


Cumulative Revenue growth Comment
Although Compugen Ltd's Annual Revenue growth year on year were below company's average 465.76% , Revenue announced in the Dec 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 161.14% year on year, from -16.72% in Dec 31 2024.

Among companies within the Healthcare sector 13 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 22 to 28.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 6
Healthcare Sector # 14
Overall # 28

Revenue TTM Y/Y Growth Statistics
High Average Low
1366.53 %
 465.76 %
25 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 22
S&P 500 # 55
Cumulative Revenue growth Comment
Although Compugen Ltd's Annual Revenue growth year on year were below company's average 465.76% , Revenue announced in the Dec 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 161.14% year on year, from -16.72% in Dec 31 2024.

Among companies within the Healthcare sector 13 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 22 to 28.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 6
Healthcare Sector # 14
Overall # 28

Revenue TTM Y/Y Growth Statistics
High Average Low
1366.53 %
465.76 %
25 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 22
S&P 500 # 55




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CGEN's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Beam Therapeutics Inc 279.52%$ 279.516 millions
Meiragtx Holdings Plc252.33%$ 252.333 millions
Star Equity Holdings Inc 232.22%$ 232.220 millions
Ethema Health Corporation 228.03%$ 228.030 millions
Foghorn Therapeutics Inc 223.77%$ 223.775 millions
Madrigal Pharmaceuticals Inc 210.77%$ 210.766 millions
Biocryst Pharmaceuticals Inc 209.09%$ 209.087 millions
Prenetics Global Limited201.94%$ 201.941 millions
Prokidney Corp 196.05%$ 196.053 millions
Mesoblast Limited191.39%$ 191.393 millions
Northwest Biotherapeutics Inc190.91%$ 190.909 millions
Zevra Therapeutics Inc 183.36%$ 183.360 millions
Spero Therapeutics Inc 174.51%$ 174.508 millions
Taysha Gene Therapies Inc 171.27%$ 171.266 millions
Compugen Ltd161.14%$ 161.140 millions
Nyxoah Sa156.29%$ 156.287 millions
Nuo Therapeutics Inc 153.57%$ 153.570 millions
Anaptysbio Inc 151.08%$ 151.082 millions
Theravance Biopharma inc 144.70%$ 144.700 millions
Voyager Therapeutics Inc 144.28%$ 144.282 millions
Esperion Therapeutics Inc 143.73%$ 143.725 millions
Foxo Technologies Inc 141.54%$ 141.542 millions
Volitionrx Limited133.25%$ 133.247 millions
Lineage Cell Therapeutics Inc 130.40%$ 130.404 millions
Tarsus Pharmaceuticals Inc 128.39%$ 128.388 millions
Evaxion A125.12%$ 125.120 millions
Cybin Inc 123.74%$ 123.742 millions
Elite Pharmaceuticals Inc 119.23%$ 119.225 millions
Pavmed Inc 116.67%$ 116.667 millions
Macrogenics Inc 113.03%$ 113.032 millions


About Compugen Ltd Revenue Growth Rates (CGEN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Compugen Ltd (CIK 1119774).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001178913-26-000663
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Compugen Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.